keyword
MENU ▼
Read by QxMD icon Read
search

ovarian cancer cytoreduction

keyword
https://www.readbyqxmd.com/read/28438874/partial-cystectomy-for-atypical-isolated-recurrence-of-ovarian-adenocarcinoma-a-case-report-and-literature-review
#1
Nicolae Bacalbasa, Irina Balescu
BACKGROUND: Most cases with advanced-stage epithelial ovarian malignancies will experience recurrent disease at a certain moment of their evolution, even if maximal cytoreductive surgery has been performed at the moment of initial diagnosis. However, it seems that the best therapeutic strategy, in case of relapse, remains aggressive re-resection, with complete cytoreduction being the most efficient way to improve survival. MATERIALS AND METHODS: We present the case of a 55-year-old patient diagnosed with an isolated pelvic recurrence after stage IIIC surgically-treated ovarian cancer three years after primary cytoreduction...
May 2017: In Vivo
https://www.readbyqxmd.com/read/28438473/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction-in-recurrent-platinum-sensitive-ovarian-cancer-nrg-oncology-gynecologic-oncology-group-study-gog-0213-a-multicentre-open-label-randomised-phase-3-trial
#2
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley, Susan A Davidson, Stephen C Rubin, Paul DiSilvestro, Karen Basen-Engquist, Helen Huang, John K Chan, Nick M Spirtos, Raheela Ashfaq, Robert S Mannel
BACKGROUND: Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. METHODS: The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre)...
April 21, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28430350/1st-evidence-based-italian-consensus-conference-on-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-carcinosis-from-ovarian-cancer
#3
Davide Cavaliere, Roberto Cirocchi, Federico Coccolini, Anna Fagotti, Massimiliano Fambrini, Orietta Federici, Domenica Lorusso, Marco Vaira, Marco Ceresoli, Paolo Delrio, Alfredo Garofalo, Sandro Pignata, Paolo Scollo, Vito Trojano, Andrea Amadori, Luca Ansaloni, Giuseppe Cariti, Franco De Cian, Pierandrea De Iaco, Michele De Simone, Marcello Deraco, Annibale Donini, Giammaria Fiorentini, Luigi Frigerio, Stefano Greggi, Antonio Macrì, Enrico Maria Pasqual, Franco Roviello, Paolo Sammartino, Cinzia Sassaroli, Giovanni Scambia, Carlo Staudacher, Patrizia Vici, Enrico Vizza, Mario Valle
Ovarian cancer (OC) remains relatively rare, although it is among the top 4 causes of cancer death for women younger than 50. The aggressive nature of the disease and its often late diagnosis with peritoneal involvement have an impact on prognosis. The current scientific literature presents ambiguous or uncertain indications for management of peritoneal carcinosis (PC) from OC, both owing to the lack of sufficient scientific data and their heterogeneity or lack of consistency. Therefore, the Italian Society of Surgical Oncology (SICO), the Italian Society of Obstetrics and Gynaecology, the Italian Association of Hospital Obstetricians and Gynaecologists, and the Italian Association of Medical Oncology conducted a multidisciplinary consensus conference (CC) on management of advanced OC presenting with PC during the SICO annual meeting in Naples, Italy, on September 10-11, 2015...
April 20, 2017: Tumori
https://www.readbyqxmd.com/read/28406844/the-role-of-he4-a-novel-biomarker-in-predicting-optimal-cytoreduction-after-neoadjuvant-chemotherapy-in-advanced-ovarian-cancer
#4
Francesco Plotti, Giuseppe Scaletta, Stella Capriglione, Roberto Montera, Daniela Luvero, Salvatore Lopez, Alessandra Gatti, Carlo De Cicco Nardone, Corrado Terranova, Roberto Angioli
OBJECTIVES: This study aimed to evaluate serum human epididymis protein 4 (HE4) changes during neoadjuvant chemotherapy (NACT) to establish HE4 predebulking surgery cutoff values and to demonstrate that CA125, HE4, and computed tomography (CT) taken together are better able to predict complete cytoreduction after NACT in advanced ovarian cancer patients. METHODS: From January 2006 to November 2015, patients affected by epithelial advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III-IV), considered not optimally resectable, were included in this prospective study...
May 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28389144/clear-cell-carcinomas-of-the-ovary-have-poorer-outcomes-compared-with-serous-carcinomas-results-from-a-single-center-taiwanese-study
#5
Fei-Chun Ku, Ren-Chin Wu, Lan-Yan Yang, Yun-Hsin Tang, Wei-Yang Chang, Jung-Erh Yang, Chun-Chieh Wang, Shih-Ming Jung, Cheng-Tao Lin, Ting-Chang Chang, Angel Chao, Chyong-Huey Lai
BACKGROUND/PURPOSE: To compare the clinical outcomes of Taiwanese patients with ovarian clear cell carcinomas (CCCs) and serous carcinomas (SCs). METHODS: We retrieved the clinical records of women with epithelial ovarian cancer (Stage I-IV) who received primary surgeries between 2000 and 2013. Cancer-specific survival (CSS), progression-free survival, and survival after recurrence (SAR) of CCC and SC patients were retrospectively compared. Multivariate analysis was used to identify the independent predictors of survival...
April 4, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28373041/-intraperitoneal-photodynamic-therapy-for-peritoneal-metastasis-of-epithelial-ovarian-cancer-limits-and-future-prospects
#6
H Azaïs, S Mordon, P Collinet
High peritoneal recurrence rate in advanced epithelial ovarian cancer after complete macroscopic cytoreductive surgery and platinum-based chemotherapy, raises the issue of peritoneal microscopic disease management and requires the development of additional locoregional treatment strategies. Photodynamic therapy is an effective treatment already applied in other medical and surgical indications. After administration of a photosensitizer which accumulates in cancer cells, illumination with a light of adequate wavelength may induce photochemical reaction between photosensitizer and tissue oxygen which lead to reactive oxygen species production and cytotoxic phenomenon...
March 31, 2017: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/28366546/trends-and-factors-associated-with-radical-cytoreductive-surgery-in-the-united-states-a-case-for-centralized-care
#7
A K Sinno, X Li, R E Thompson, E J Tanner, K L Levinson, R L Stone, S M Temkin, A N Fader, D S Chi, K Long Roche
OBJECTIVES: To describe the US national trends and factors associated with cytoreductive surgical radicality in women with advanced ovarian cancer (OC). METHODS: An analysis of the National Inpatient Sample database was performed. All admissions from 1993 to 2011 for advanced OC cytoreductive surgery (CRS) were identified and categorized as simple pelvic (SP), extensive pelvic (EP), and extensive upper abdominal (EUA) surgery. Annual trends in CRS were analyzed...
March 30, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28365932/usefulness-of-human-epididymis-protein-4-in-predicting-optimal-cytoreductive-therapy-in-patients-with-advanced-ovarian-cancer
#8
Vesna Paunovic, Zoran Protrka, Daniela Ardalic, Tomislav Paunovic
PURPOSE: Human Epididymis Protein 4 (HE4) is a novel promising serum biomarker of high sensitivity and specificity for ovarian cancer (OC). We investigated the usefulness of HE4 in predicting the outcome of surgery of advanced OC. METHODS: Fifty patients with OC (FIGO stage III and IV) entered the study. Serum concentrations of HE4 and CA125 were evaluated preoperatively. All patients had been operated between January 2014 - January 2016. RESULTS: Preoperatively, the mean concentration of HE4 was 628pmol/L...
January 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28359805/-specific-folic-acid-targeted-photosensitizer-the-first-step-toward-intraperitoneal-photodynamic-therapy-for-epithelial-ovarian-cancer
#9
H Azaïs, C Frochot, A Grabarz, S Khodja Bach, L Colombeau, N Delhem, S Mordon, P Collinet
OBJECTIVE: Epithelial ovarian cancer (EOC) management remains association of debulking surgery in combination with platinum-based chemotherapy. Sixty percent of women with EOC considered in remission will develop recurrent disease. An option to improve the completion of cytoreductive surgery may be the use of photodynamic therapy to induce necrosis of peritoneal metastases. A limit of this technique was the toxicity induced by the lack of specificity of old-generation photosensitizer (PS) for tumor tissue if the light could not be specifically applied...
March 27, 2017: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/28317584/dealing-with-microscopic-peritoneal-metastases-of-epithelial-ovarian-cancer-a-surgical-challenge
#10
REVIEW
Henri Azaïs, Juan Pablo Estevez, Périne Foucher, Yohan Kerbage, Serge Mordon, Pierre Collinet
Understanding biology and progression mechanisms of peritoneal metastases of epithelial ovarian cancer (EOC) is a cornerstone in the knowledge and the comprehensive management of the disease. Despite clinical remission after the association of complete cytoreductive surgery and platinum-based chemotherapy, peritoneal recurrence still occurs in 60% of patients. Eligible studies, published from 1980 to June 2016, were retrieved through ClinicalTrials.gov, MEDLINE, Cochrane databases and bibliography searches...
March 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28317007/the-role-of-neoadjuvant-chemotherapy-in-the-management-of-patients-with-advanced-stage-ovarian-cancer-survey-results-from-members-of-the-society-of-gynecologic-oncologists-a-5-year-follow-up
#11
Erica Huelsmann, Israel Zighelboim, Amina Ahmed, Summer Dewdney
•NACT use among SGO members for ovarian cancer is explored given recent trials.•Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.•Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.•Very high optimal cytoreduction rates are reported from SGO members.•Despite recent studies, SGO members don't regularly treat patients with NACT/ID.
May 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28316851/pure-primary-ovarian-squamous-cell-carcinoma-perforating-the-rectum
#12
Kazuya Mimura, Aiko Okada, Naotsugu Haraguchi, Kenjiro Sawada, Takuji Tomimatsu, Tadashi Kimura
Rectal perforation is uncommon in ovarian cancer, even in advanced stages. Pure primary ovarian squamous cell carcinoma is a very rare subtype of ovarian cancer and has not been reported to cause rectal perforation. A 50-year-old woman presented with rectal bleeding. Rectosigmoidoscopy suggested perforation of a pelvic tumor into the rectum. Abdominopelvic magnetic resonance imaging revealed a 9 cm heterogeneous mass in the pouch of Douglas. We performed complete cytoreduction, including an en-bloc resection of the tumor and rectosigmoid colon...
2017: Case Reports in Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28285846/a-comparative-analysis-of-prediction-models-for-complete-gross-resection-in-secondary-cytoreductive-surgery-for-ovarian-cancer
#13
Renee A Cowan, Ane Gerda Zahl Eriksson, Sara M Jaber, Qin Zhou, Alexia Iasonos, Oliver Zivanovic, Mario M Leitao, Nadeem R Abu-Rustum, Dennis S Chi, Ginger J Gardner
OBJECTIVE: We sought to examine compliance and outcomes using Memorial Sloan Kettering "(MSK) criteria" to predict complete gross resection (CGR) and compare them with the validated Tian and AGO models. METHODS: Patients who underwent SCS for recurrent platinum-sensitive ovarian cancer from 5/2001-6/2014 were identified. The AGO and Tian models were applied to the study population; appropriate statistical tests were used to determine ability to predict CGR. RESULTS: 214 SCS cases were identified...
March 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28254228/difficulty-in-diagnosis-and-different-prognoses-between-colorectal-cancer-with-ovarian-metastasis-and-advanced-ovarian-cancer-an-empirical-study-of-different-surgical-adoptions
#14
Ko-Chao Lee, Hao Lin, Chan-Chao ChangChien, Hung-Chun Fu, Ching-Chou Tsai, Chen-Hsuan Wu, Yu-Che Ou
OBJECTIVE: To determine the clinical manifestations and optimal management of female patients with advanced colorectal cancer (CRC) metastasis in ovaries mimicking advanced ovarian malignancy. MATERIALS AND METHODS: A retrospective medical records review of female patients with primary CRC metastasis to ovaries, which were initially diagnosed as ovarian malignancy, and treated between 2001 and 2013. Clinical presentations, pathologic findings, and treatment outcomes were analyzed...
February 2017: Taiwanese Journal of Obstetrics & Gynecology
https://www.readbyqxmd.com/read/28238354/optimal-primary-management-of-bulky-stage-iiic-ovarian-fallopian-tube-and-peritoneal-carcinoma-are-the-only-options-complete-gross-resection-at-primary-debulking-surgery-or-neoadjuvant-chemotherapy
#15
Vasileios D Sioulas, Maria B Schiavone, David Kadouri, Oliver Zivanovic, Kara Long Roche, Roisin O'Cearbhaill, Nadeem R Abu-Rustum, Douglas A Levine, Yukio Sonoda, Ginger J Gardner, Mario M Leitao, Dennis S Chi
OBJECTIVE: To explore the impact of primary debulking surgery (PDS) to minimal but gross residual disease (RD) in women with bulky stage IIIC ovarian, fallopian tube, or primary peritoneal cancer. METHODS: We retrospectively reviewed all patients with the aforementioned diagnosis who underwent PDS at our institution from 01/2001-12/2010. Those with disease of non-epithelial histology or borderline tumors were excluded. Clinicopathologic data were abstracted, and appropriate statistical tests were used...
April 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28210074/second-look-surgery-plus-hyperthermic-intraperitoneal-chemotherapy-for-patients-with-colorectal-cancer-at-high-risk-of-peritoneal-carcinomatosis-does-it-really-save-lives
#16
EDITORIAL
Delia Cortes-Guiral, Dominique Elias, Pedro Antonio Cascales-Campos, Alfredo Badía Yébenes, Ismael Guijo Castellano, Ana Isabel León Carbonero, José Ignacio Martín Valadés, Jesus Garcia-Foncillas, Damian Garcia-Olmo
The treatment of peritoneal carcinomatosis (PC) of colorectal origin with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has a 5-year recurrence-free or cure rate of at least 16%, so it is no longer labeled as a fatal disease, and offers prolonged survival for patients with a low peritoneal carcinomatosis index. Metachronous PC of colorectal origin is so predictable that there is a model which has been used to successfully determine the individual risk of each patient. Patients at risk are clearly identified; those with the highest risk have small peritoneal nodules present in the first surgery (70% probability of developing PC), ovarian metastases (60%), perforated tumor onset or intraoperative tumor rupture (50%)...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28209497/a-multicenter-assessment-of-the-ability-of-preoperative-computed-tomography-scan-and-ca-125-to-predict-gross-residual-disease-at-primary-debulking-for-advanced-epithelial-ovarian-cancer
#17
Rudy S Suidan, Pedro T Ramirez, Debra M Sarasohn, Jerrold B Teitcher, Revathy B Iyer, Qin Zhou, Alexia Iasonos, John Denesopolis, Oliver Zivanovic, Kara C Long Roche, Yukio Sonoda, Robert L Coleman, Nadeem R Abu-Rustum, Hedvig Hricak, Dennis S Chi
OBJECTIVE: To assess the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease (RD) at primary cytoreduction in advanced ovarian cancer. METHODS: A prospective, non-randomized, multicenter trial of patients who underwent primary debulking for stage III-IV epithelial ovarian cancer previously identified 9 criteria associated with suboptimal (>1cm residual) cytoreduction. This is a secondary post-hoc analysis looking at the ability to predict any RD...
April 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28187098/preoperative-predictive-factors-for-complete-cytoreduction-and-survival-outcome-in-epithelial-ovarian-tubal-and-peritoneal-cancer-after-neoadjuvant-chemotherapy
#18
Min-Hyun Baek, Shin-Wha Lee, Jeong-Yeol Park, Chae Chun Rhim, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
OBJECTIVE: The study aims to identify preoperative predictors of complete cytoreduction and early recurrence and death in epithelial ovarian, tubal, and peritoneal cancer after neoadjuvant chemotherapy (NACT). METHODS: We performed a retrospective analysis of 85 patients who underwent 3 cycles of NACT. Patients were divided into 2 groups according to residual tumor at interval debulking surgery (IDS), and clinicopathologic, surgical, and follow-up data were compared...
March 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28174234/ct-perfusion-as-an-early-biomarker-of-treatment-efficacy-in-advanced-ovarian-cancer-an-acrin-and-gog-study
#19
Chaan Ng, Zheng Zhang, Susanna I Lee, Helga S Marques, Kyle Burgers, Feng Su, Joseph Bauza, Robert S Mannel, Joan Walker, Warner K Huh, Stephen C Rubin, Paul DiSilvestro, Lainie P Martin, John K Chan, Michael A Bookman, Robert L Coleman, Ting-Yim Lee
PURPOSE: ACRIN 6695 was a feasibility study investigating whether CT perfusion (CTP) biomarkers are associated with progression-free survival at 6 months (PFS-6) in patients with advanced ovarian cancer who were treated with carboplatin and either dose-dense (weekly) or conventional (3-weekly) paclitaxel, with optional bevacizumab in the prospective phase III GOG-0262 trial. EXPERIMENTAL DESIGN: ACRIN 6695 recruited participants with residual disease after primary cytoreductive surgery or planned interval cytoreduction following neoadjuvant therapy, to undergo CTP studies before (T0), 3-weeks (T1) and 4-weeks (T2) after chemotherapy initiation...
February 7, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28159443/the-influence-of-sarcopenia-on-survival-and-surgical-complications-in-ovarian-cancer-patients-undergoing-primary-debulking-surgery
#20
I J G Rutten, J Ubachs, R F P M Kruitwagen, D P J van Dijk, R G H Beets-Tan, L F A G Massuger, S W M Olde Damink, T Van Gorp
BACKGROUND: Sarcopenia, severe skeletal muscle loss, has been identified as a prognostic factor in various malignancies. This study aims to investigate whether sarcopenia is associated with overall survival (OS) and surgical complications in patients with advanced ovarian cancer undergoing primary debulking surgery (PDS). METHODS: Ovarian cancer patients (n = 216) treated with PDS were enrolled retrospectively. Total skeletal muscle surface area was measured on axial computed tomography at the level of the third lumbar vertebra...
April 2017: European Journal of Surgical Oncology
keyword
keyword
111476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"